[F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: Clinical outcomes and patterns of failure

James G. Douglas, Keith J. Stelzer, David A. Mankoff, Kevin S. Tralins, Kenneth A. Krohn, Mark Muzi, Daniel L. Silbergeld, Robert C. Rostomily, Jeffrey Scharnhorst, Alexander M. Spence

Research output: Research - peer-reviewArticle

  • 36 Citations

Abstract

Purpose: [F-18]-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging for brain tumors has been shown to identify areas of active disease. Radiation dose escalation in the treatment of glioblastoma multiforme may lead to improved disease control. Based on these premises, we initiated a prospective study of FDG-PET for the treatment planning of radiation dose escalation for the treatment of glioblastoma multiforme. Methods and Materials: Forty patients were enrolled. Patients were treated with standard conformal fractionated radiotherapy with volumes defined by MRI imaging. When patients reached a dose of 45-50.4 Gy, they underwent FDG-PET imaging for boost target delineation, for an additional 20 Gy (2 Gy per fraction) to a total dose of 79.4 Gy (n = 30). Results: The estimated 1-year and 2-year overall survival (OS) for the entire group was 70% and 17%, respectively, with a median overall survival of 70 weeks. The estimated 1-year and 2-year progression-free survival (PFS) was 18% and 3%, respectively, with a median of 24 weeks. No significant improvements in OS or PFS were observed for the study group in comparison to institutional historical controls. Conclusions: Radiation dose escalation to 79.4 Gy based on FDG-PET imaging demonstrated no improvement in OS or PFS. This study establishes the feasibility of integrating PET metabolic imaging into radiotherapy treatment planning.

LanguageEnglish (US)
Pages886-891
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume64
Issue number3
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Glioblastoma
Positron-Emission Tomography
Radiation
Survival
Therapeutics
positrons
tomography
dosage
radiation
Disease-Free Survival
progressions
planning
radiation therapy
Conformal Radiotherapy
Feasibility Studies
Brain Neoplasms
Radiotherapy
Prospective Studies
delineation

Keywords

  • Dose escalation GBM
  • Glioblastoma multiforme
  • PET
  • Radiotherapy for glioblastoma multiforme

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

[F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme : Clinical outcomes and patterns of failure. / Douglas, James G.; Stelzer, Keith J.; Mankoff, David A.; Tralins, Kevin S.; Krohn, Kenneth A.; Muzi, Mark; Silbergeld, Daniel L.; Rostomily, Robert C.; Scharnhorst, Jeffrey; Spence, Alexander M.

In: International Journal of Radiation Oncology Biology Physics, Vol. 64, No. 3, 01.03.2006, p. 886-891.

Research output: Research - peer-reviewArticle

Douglas, James G. ; Stelzer, Keith J. ; Mankoff, David A. ; Tralins, Kevin S. ; Krohn, Kenneth A. ; Muzi, Mark ; Silbergeld, Daniel L. ; Rostomily, Robert C. ; Scharnhorst, Jeffrey ; Spence, Alexander M./ [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme : Clinical outcomes and patterns of failure. In: International Journal of Radiation Oncology Biology Physics. 2006 ; Vol. 64, No. 3. pp. 886-891
@article{d2a30b97e018409290fa902e81fa7289,
title = "[F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: Clinical outcomes and patterns of failure",
abstract = "Purpose: [F-18]-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging for brain tumors has been shown to identify areas of active disease. Radiation dose escalation in the treatment of glioblastoma multiforme may lead to improved disease control. Based on these premises, we initiated a prospective study of FDG-PET for the treatment planning of radiation dose escalation for the treatment of glioblastoma multiforme. Methods and Materials: Forty patients were enrolled. Patients were treated with standard conformal fractionated radiotherapy with volumes defined by MRI imaging. When patients reached a dose of 45-50.4 Gy, they underwent FDG-PET imaging for boost target delineation, for an additional 20 Gy (2 Gy per fraction) to a total dose of 79.4 Gy (n = 30). Results: The estimated 1-year and 2-year overall survival (OS) for the entire group was 70% and 17%, respectively, with a median overall survival of 70 weeks. The estimated 1-year and 2-year progression-free survival (PFS) was 18% and 3%, respectively, with a median of 24 weeks. No significant improvements in OS or PFS were observed for the study group in comparison to institutional historical controls. Conclusions: Radiation dose escalation to 79.4 Gy based on FDG-PET imaging demonstrated no improvement in OS or PFS. This study establishes the feasibility of integrating PET metabolic imaging into radiotherapy treatment planning.",
keywords = "Dose escalation GBM, Glioblastoma multiforme, PET, Radiotherapy for glioblastoma multiforme",
author = "Douglas, {James G.} and Stelzer, {Keith J.} and Mankoff, {David A.} and Tralins, {Kevin S.} and Krohn, {Kenneth A.} and Mark Muzi and Silbergeld, {Daniel L.} and Rostomily, {Robert C.} and Jeffrey Scharnhorst and Spence, {Alexander M.}",
year = "2006",
month = "3",
doi = "10.1016/j.ijrobp.2005.08.013",
volume = "64",
pages = "886--891",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme

T2 - International Journal of Radiation Oncology Biology Physics

AU - Douglas,James G.

AU - Stelzer,Keith J.

AU - Mankoff,David A.

AU - Tralins,Kevin S.

AU - Krohn,Kenneth A.

AU - Muzi,Mark

AU - Silbergeld,Daniel L.

AU - Rostomily,Robert C.

AU - Scharnhorst,Jeffrey

AU - Spence,Alexander M.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Purpose: [F-18]-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging for brain tumors has been shown to identify areas of active disease. Radiation dose escalation in the treatment of glioblastoma multiforme may lead to improved disease control. Based on these premises, we initiated a prospective study of FDG-PET for the treatment planning of radiation dose escalation for the treatment of glioblastoma multiforme. Methods and Materials: Forty patients were enrolled. Patients were treated with standard conformal fractionated radiotherapy with volumes defined by MRI imaging. When patients reached a dose of 45-50.4 Gy, they underwent FDG-PET imaging for boost target delineation, for an additional 20 Gy (2 Gy per fraction) to a total dose of 79.4 Gy (n = 30). Results: The estimated 1-year and 2-year overall survival (OS) for the entire group was 70% and 17%, respectively, with a median overall survival of 70 weeks. The estimated 1-year and 2-year progression-free survival (PFS) was 18% and 3%, respectively, with a median of 24 weeks. No significant improvements in OS or PFS were observed for the study group in comparison to institutional historical controls. Conclusions: Radiation dose escalation to 79.4 Gy based on FDG-PET imaging demonstrated no improvement in OS or PFS. This study establishes the feasibility of integrating PET metabolic imaging into radiotherapy treatment planning.

AB - Purpose: [F-18]-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging for brain tumors has been shown to identify areas of active disease. Radiation dose escalation in the treatment of glioblastoma multiforme may lead to improved disease control. Based on these premises, we initiated a prospective study of FDG-PET for the treatment planning of radiation dose escalation for the treatment of glioblastoma multiforme. Methods and Materials: Forty patients were enrolled. Patients were treated with standard conformal fractionated radiotherapy with volumes defined by MRI imaging. When patients reached a dose of 45-50.4 Gy, they underwent FDG-PET imaging for boost target delineation, for an additional 20 Gy (2 Gy per fraction) to a total dose of 79.4 Gy (n = 30). Results: The estimated 1-year and 2-year overall survival (OS) for the entire group was 70% and 17%, respectively, with a median overall survival of 70 weeks. The estimated 1-year and 2-year progression-free survival (PFS) was 18% and 3%, respectively, with a median of 24 weeks. No significant improvements in OS or PFS were observed for the study group in comparison to institutional historical controls. Conclusions: Radiation dose escalation to 79.4 Gy based on FDG-PET imaging demonstrated no improvement in OS or PFS. This study establishes the feasibility of integrating PET metabolic imaging into radiotherapy treatment planning.

KW - Dose escalation GBM

KW - Glioblastoma multiforme

KW - PET

KW - Radiotherapy for glioblastoma multiforme

UR - http://www.scopus.com/inward/record.url?scp=31844453730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31844453730&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2005.08.013

DO - 10.1016/j.ijrobp.2005.08.013

M3 - Article

VL - 64

SP - 886

EP - 891

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -